Jena Amarnath, Taneja Sangeeta, Singh Aru, Negi Pradeep, Mehta Shashi Bhushan, Ahuja Aashim, Singhal Manish, Sarin Ramesh
Department of Molecular Imaging and Nuclear Medicine, Indraprastha Apollo Hospitals, SaritaVihar, Delhi-Mathura Road, New Delhi 110076, India.
Department of Molecular Imaging and Nuclear Medicine, Indraprastha Apollo Hospitals, SaritaVihar, Delhi-Mathura Road, New Delhi 110076, India.
Eur J Radiol. 2017 Jul;92:30-36. doi: 10.1016/j.ejrad.2017.04.013. Epub 2017 Apr 23.
To study relationships among pharmacokinetic and F-fluorodeoxyglucose (F-FDG) PET parameters obtained through simultaneous PET/MRI in breast cancer patients and evaluate their combined potential for response evaluation.
The study included 41 breast cancer patients for correlation study and 9 patients (pre and post therapy) for response evaluation. All patients underwent simultaneous PET/MRI with dedicated breast imaging. Pharmacokinetic parameters and PET parameters for tumor were derived using an in- house developed and vendor provided softwares respectively. Relationships between SUV and pharmacokinetic parameters and clinical as well as histopathologic parameters were evaluated using Spearman correlation analysis. Response to chemotherapy was derived as percentage reduction in size and in parameters post therapy.
Significant correlations were observed between SUVmean, max, peak, TLG with K (ρ=0.446, 0.417, 0.491, 0.430; p≤0.01); with Kep(ρ=0.303, ρ=0.315, ρ=0.319; p≤0.05); and with iAUC(ρ=0.401, ρ=0.410, ρ=0.379; p≤0.05, p≤0.01). The ratio of ve/iAUC showed significant negative correlation to SUVmean, max, peak and TLG (ρ=0.420, 0.446, 0.443, 0.426; p≤0.01). Ability of SUV as well as pharmacokinetic parameters to predict response to therapy matched the RECIST criteria in 9 out of 11 lesions in 9 patients. Maximum post therapy quantitative reduction was observed in SUVpeak, TLG and K.
Simultaneous PET/MRI enables illustration of close interactions between glucose metabolism and pharmacokinetic parameters in breast cancer patients and potential of their simultaneity in response assessment to therapy.
研究乳腺癌患者通过同步正电子发射断层扫描/磁共振成像（PET/MRI）获得的药代动力学参数与氟脱氧葡萄糖（F-FDG）PET参数之间的关系，并评估它们在疗效评估中的联合潜力。
该研究纳入了41例乳腺癌患者进行相关性研究，以及9例患者（治疗前后）进行疗效评估。所有患者均接受了带有专用乳腺成像的同步PET/MRI检查。肿瘤的药代动力学参数和PET参数分别使用内部开发的软件和供应商提供的软件得出。使用Spearman相关性分析评估SUV与药代动力学参数、临床以及组织病理学参数之间的关系。化疗疗效通过治疗后尺寸和参数的减少百分比得出。
观察到SUVmean、max、peak、TLG与K之间存在显著相关性（ρ=0.446、0.417、0.491、0.430；p≤0.01）；与Kep之间存在显著相关性（ρ=0.303、ρ=0.315、ρ=0.319；p≤0.05）；与iAUC之间存在显著相关性（ρ=0.401、ρ=0.410、ρ=0.379；p≤0.05、p≤0.01）。ve/iAUC比值与SUVmean、max、peak和TLG呈显著负相关（ρ=0.420、0.446、0.443、0.426；p≤0.01）。在9例患者的11个病灶中，有9个病灶的SUV以及药代动力学参数预测治疗反应的能力与实体瘤疗效评价标准（RECIST）相符。治疗后SUVpeak、TLG和K的定量减少最大。
同步PET/MRI能够阐明乳腺癌患者葡萄糖代谢与药代动力学参数之间的密切相互作用，以及它们在治疗反应评估中的联合潜力。
